ML14119A043

Affidavit for Shine Medical Technologies, Inc. Discussion Notes Associated with March 20, 2014 Meeting

ML14119A043
Person / Time
Site:	SHINE Medical Technologies
Issue date:	03/17/2014
From:	Bynum R SHINE Medical Technologies
To:	Office of Nuclear Reactor Regulation
References
Download: ML14119A043 (2)

Text

• SHINE Medical Technologies AFFIDAVIT OF RICHARD VANN BYNUM STATE OF WISCONSIN

) ss.

COUNTY OF DANE I, Richard Vann Bynum, Chief Operating Officer of SHINE Medical Technologies, Inc. (SHINE),

do hereby affirm and state:

1.

I am authorized to execute this affidavit on behalf of SHINE. I am authorized to review information submitted to or discussed with the Nuclear Regulatory Commission (NRC) and apply for the withholding of information from public disclosure. The purpose of this affidavit is to provide the information required by 10 CFR 2.390(b) in support of SHINE's request for proprietary treatment of certain confidential commercial information contained in the SHINE Medical Technologies, Inc. Discussion Notes Associated with March 20, 2014 Meeting with NRC. SHINE requests that the confidential information contained in the SHINE Medical Technologies, Inc. Discussion Notes Associated with March 20, 2014 Meeting with NRC be withheld from public disclosure.

2.

I have knowledge of the criteria used by SHINE in designating information as sensitive, proprietary, or confidential.

3.

Pursuant to the provisions of paragraph (a)(4) of 10 CFR 2.390, the following is furnished for NRC consideration in determining whether the information sought to be withheld from public disclosure should be withheld.

a. The information sought to be withheld from public disclosure contained in the SHINE Medical Technologies, Inc. Discussion Notes Associated with March 20, 2014 Meeting with NRC is owned by SHINE, its affiliates or third parties to whom SHINE has an obligation to maintain its confidentiality. This information is and has been held in confidence by SHINE.

b. The information sought to be protected in the SHINE Medical Technologies, Inc. Discussion Notes Associated with March 20, 2014 Meeting with NRC is not available to the public to the best of my knowledge and belief.

1

c. The information contained in the SHINE Medical Technologies, Inc.

Discussion Notes Associated with March 20, 2014 Meeting with NRC is of the type that is customarily held in confidence by SHINE, and there is a rational basis for doing so. The information that SHINE is requesting to be withheld from public disclosure includes trade secret, commercial information or information that is subject to export controls. SHINE limits access to these elements to those individuals with a "need to know," and subject those individuals to maintaining confidentiality.

d. The proprietary information sought to be withheld from public disclosure in the SHINE Medical Technologies, Inc. Discussion Notes Associated with March 20, 2014 Meeting with NRC includes, but is not limited to: structural configuration, primary and supporting systems of the medical isotope facility, process and system locations, and process details. This would include information regarding the types, quantities, and locations of materials stored on site as would be referenced in facility configuration drawings. Public disclosure of the information in the SHINE Medical Technologies, Inc.

Discussion Notes Associated with March 20, 2014 Meeting with NRC would create substantial harm to SHINE because it would reveal trade secrets owned by SHINE, its affiliates or third parties to whom SHINE has an obligation to maintain its confidentiality.

e. The information contained in the SHINE Medical Technologies, Inc.

Discussion Notes Associated with March 20, 2014 Meeting with NRC is transmitted to the NRC in confidence and under the provisions of 10 CFR 2.390; it is to be received in confidence by the NRC. The information is properly marked.

I declare under the penalty of perjury that the foregoing is true and correct.

Executed on March 17, 2014.

Richard VanBynum, Ph.D.

COO - SHINE Medical Technologies, Inc.

2